Crescita Therapeutics Inc.

As of March 31, 2026, Crescita Therapeutics Inc. has 18.61M shares outstanding.

As of March 31, 2026, Crescita Therapeutics Inc. trades at a trailing price-to-earnings ratio of 14.76. The price-to-sales ratio is 0.60, and the price-to-book ratio stands at 0.96.

As of March 31, 2026, Crescita Therapeutics Inc. trades at an EV/EBITDA multiple of 20.45 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.33 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Crescita Therapeutics Inc. trades at an EV/FCF ratio of 3.65, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of March 31, 2026, Crescita Therapeutics Inc. maintains a current ratio of 2.80, meaning it holds 2.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 17.34, indicating elevated leverage, while an interest coverage ratio of 6.17 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended March 31, 2026, Crescita Therapeutics Inc. posted a negative return on equity (ROE) of -2.19, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -1.46, reflecting losses generated across the asset base. Return on capital employed (ROCE) is negative at -4.18, pointing to unprofitable operations over the period. Inventory turnover of 2.42 indicates how many times Crescita Therapeutics Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, Crescita Therapeutics Inc. posted a gross margin of 51.71, reflecting its pricing power and cost economics. The operating margin of -5.02 and net profit margin of -1.38 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield stands at 14.44, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 4.99, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Crescita Therapeutics Inc. shareholders.

Crescita Therapeutics Inc.'s most recent stock split took place on February 6, 2018 with a 200:209 split ratio.

As of March 31, 2026, Crescita Therapeutics Inc. has an Altman Z-Score of -0.55, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.